Scholar Rock - Discovery and Development of Innovative Medicines
2 days ago · Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin. Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024.
See Our Press Releases - Scholar Rock, Inc.
November 4, 2024. Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin. Read This Press Release. November 1, 2024. Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024.
Scholar Rock to Advance Antimyostatin Program to Develop Novel ...
Company plans to expand into cardiometabolic disorders, leveraging its experience in myostatin inhibition. Preclinical data support advancing SRK-439, a novel investigational myostatin inhibitor for the treatment of cardiometabolic disorders, with an initial focus on obesity, towards an IND submission in 2025.
Scholar Rock to Participate in Upcoming Investor Conferences
Feb 28, 2024 · Scholar Rock to Participate in Upcoming Investor Conferences. TD Cowen 44 th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 9:10 a.m. ET on Tuesday, March 5 in Boston . 3 rd Annual Jefferies Biotech on the Bay Summit, March 12 in Miami, Florida .
Investor Information - Scholar Rock, Inc.
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin. Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on …
Scholar Rock Announces Positive Proof-of-Concept Data from …
Oct 27, 2020 · Patients are being treated with 20 mg/kg of SRK-015 Q4W either as a monotherapy or in conjunction with an approved SMN upregulator therapy (nusinersen). The primary objectives of the cohort are to assess safety and the mean change from baseline in Revised Hammersmith Scale (RHS).
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of …
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity. CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Sep. 10, 2024-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious ...
Scholar Rock Announces New Preclinical Data for SRK-439 …
Nov 4, 2024 · SRK-439 is a novel, preclinical, investigational myostatin inhibitor that binds to pro- and latent myostatin with high affinity and is selective for myostatin (i.e., no GDF11 or Activin-A binding), and is initially being developed for the treatment of …
Scholar Rock Provides Corporate Update and Highlights Priorities …
Jan 10, 2022 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2022-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022.
Scholar Rock Announces Proposed Public Offering of Common Stock
All of the shares are being offered by Scholar Rock. In addition, Scholar Rock intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount equal to 15% of the securities offered in the public offering.